The safety and efficacy of subcutaneous birch pollen immunotherapy - a one-year, randomised, double-blind, placebo-controlled study

U Bødtger; Lars K. Poulsen; H H Jacobi; H-J Malling

The safety and efficacy of subcutaneous birch pollen immunotherapy - a one-year, randomised, double-blind, placebo-controlled study

U Bødtger, Lars K. Poulsen, H H Jacobi, H-J Malling

85 Citations (Scopus)

Abstract

There is only very limited documentation of the efficacy and safety of high-dose subcutaneous birch pollen immunotherapy (IT) in double-blind, placebo-controlled (DBPC) studies. Birch pollen is a major cause of allergic morbidity in northern Europe and in eastern parts of North America.

Original language	English
Journal	Allergy
Volume	57
Issue number	4
Pages (from-to)	297-305
Number of pages	9
ISSN	0105-4538
Publication status	Published - Apr 2002

Keywords

Adult
Allergens
Antibody Specificity
Betula
Conjunctivitis, Allergic
Desensitization, Immunologic
Dose-Response Relationship, Immunologic
Double-Blind Method
Female
Follow-Up Studies
Humans
Immunoglobulin E
Male
Middle Aged
Pain Measurement
Phytotherapy
Pollen
Rhinitis, Allergic, Seasonal
Seasons
Sensitivity and Specificity
Severity of Illness Index
Treatment Outcome

Cite this

@article{d235495205f0491c815fb7c006dfc630,

title = "The safety and efficacy of subcutaneous birch pollen immunotherapy - a one-year, randomised, double-blind, placebo-controlled study",

abstract = "There is only very limited documentation of the efficacy and safety of high-dose subcutaneous birch pollen immunotherapy (IT) in double-blind, placebo-controlled (DBPC) studies. Birch pollen is a major cause of allergic morbidity in northern Europe and in eastern parts of North America.",

keywords = "Adult, Allergens, Antibody Specificity, Betula, Conjunctivitis, Allergic, Desensitization, Immunologic, Dose-Response Relationship, Immunologic, Double-Blind Method, Female, Follow-Up Studies, Humans, Immunoglobulin E, Male, Middle Aged, Pain Measurement, Phytotherapy, Pollen, Rhinitis, Allergic, Seasonal, Seasons, Sensitivity and Specificity, Severity of Illness Index, Treatment Outcome",

author = "U B{\o}dtger and Poulsen, {Lars K.} and Jacobi, {H H} and H-J Malling",

year = "2002",

month = apr,

language = "English",

volume = "57",

pages = "297--305",

journal = "Allergy: European Journal of Allergy and Clinical Immunology",

issn = "0105-4538",

publisher = "Wiley Online",

number = "4",

}

TY - JOUR

T1 - The safety and efficacy of subcutaneous birch pollen immunotherapy - a one-year, randomised, double-blind, placebo-controlled study

AU - Bødtger, U

AU - Poulsen, Lars K.

AU - Jacobi, H H

AU - Malling, H-J

PY - 2002/4

Y1 - 2002/4

N2 - There is only very limited documentation of the efficacy and safety of high-dose subcutaneous birch pollen immunotherapy (IT) in double-blind, placebo-controlled (DBPC) studies. Birch pollen is a major cause of allergic morbidity in northern Europe and in eastern parts of North America.

AB - There is only very limited documentation of the efficacy and safety of high-dose subcutaneous birch pollen immunotherapy (IT) in double-blind, placebo-controlled (DBPC) studies. Birch pollen is a major cause of allergic morbidity in northern Europe and in eastern parts of North America.

KW - Adult

KW - Allergens

KW - Antibody Specificity

KW - Betula

KW - Conjunctivitis, Allergic

KW - Desensitization, Immunologic

KW - Dose-Response Relationship, Immunologic

KW - Double-Blind Method

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Immunoglobulin E

KW - Male

KW - Middle Aged

KW - Pain Measurement

KW - Phytotherapy

KW - Pollen

KW - Rhinitis, Allergic, Seasonal

KW - Seasons

KW - Sensitivity and Specificity

KW - Severity of Illness Index

KW - Treatment Outcome

M3 - Journal article

C2 - 11906359

SN - 0105-4538

VL - 57

SP - 297

EP - 305

JO - Allergy: European Journal of Allergy and Clinical Immunology

JF - Allergy: European Journal of Allergy and Clinical Immunology

IS - 4

ER -

The safety and efficacy of subcutaneous birch pollen immunotherapy - a one-year, randomised, double-blind, placebo-controlled study

Abstract

Keywords

Fingerprint

Cite this